MHRA Requests Feedback Ahead of Brexit
The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) is conducting a survey to better understand how it can support its customers in the run up to the country’s exit from European Union.
MHRA is embarking on a major operational transformation scheme across its three expert centers: the MHRA regulatory center, the National Institute for Biological Standards and Control, and the Clinical Practice Research Datalink. This includes significant investment in the organization’s digital capabilities and infrastructure, it noted.
The survey should take about 10-15 minutes to complete, depending on how many different parts of the agency an individual deals with. All responses will be held in strict confidence and will not be passed on to the agency in a way that would allow any individual contribution to be identified, according to the survey organizers.
According to the MHRA, “understanding your needs and priorities is essential to inform our plans and will help us to strategically shape our services, investment decisions, and underlying operational processes and systems. The work we do now will underpin how we are able to meet your needs for years to come.”
The survey was designed in collaboration with PA Consulting, a consulting, technology, and innovation firm, and Woodnewton Associates, an independent strategic research agency. It closes on Wednesday September 27. To complete it, click here.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
